Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals

D Lapa, DM Grousova, G Matusali, S Meschi, F Colavita, A Bettini, G Gramigna, M Francalancia, AR Garbuglia, E Girardi, V Puro, A Antinori, AV Kovyrshina, View ORCID ProfileIV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, OV Zubkova, DY Logunov, BS Naroditsky, F Vaia, AL Gintsburg
doi: https://doi.org/10.1101/2022.01.15.22269335
D Lapa
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DM Grousova
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Matusali
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Meschi
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Colavita
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Bettini
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Gramigna
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Francalancia
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AR Garbuglia
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: annarosa.garbuglia@inmi.it ldenisy@gmail.com
E Girardi
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V Puro
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Antinori
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AV Kovyrshina
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IV Dolzhikova
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for IV Dolzhikova
DV Shcheblyakov
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AI Tukhvatulin
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OV Zubkova
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DY Logunov
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: annarosa.garbuglia@inmi.it ldenisy@gmail.com
BS Naroditsky
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Vaia
1INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, via Portuense 292, 00149, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AL Gintsburg
2FSBI “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation. 123098, Moscow, Russia
3Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). 119435 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The new variant Omicron (B.1.1.529) of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. The Omicron becomes the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on neutralizing activity of vaccinated sera against Omicron variant are currently being carried out in many laboratories.

In this study, we have shown the neutralizing activity of sera against SARS-CoV-2 Omicron (B.1.1.529) variant compared to the reference Wuhan D614G (B.1) variant in individuals vaccinated with 2 doses of Sputnik V or BNT162b2 in different time points up to 6 months after vaccination. We performed analysis on sample pools with comparable NtAb to Wuhan D614G variant. The decrease in neutralizing antibody (NtAb) to the Omicron variant was 8.1 folds for group of Sputnik V-vaccinated and 21.4 folds for group of BNT162b2-vaccinated. Analysis showed that 74.2% of Sputnik V- and 56.9% of BNT162b2-vaccinated sera had detectable NtAb to SARS-CoV-2 Omicron variant.

The decrease in NtAb to SARS-CoV-2 Omicron variant compared to Wuhan variant has been shown for many COVID-19 vaccines in use, with some showing no neutralization at all. Today the necessity of third booster vaccination is obvious. And the most effective approach, already shown in several studies, is the use of heterologous booster vaccination pioneered in COVID-19 vaccines by Sputnik V.

Competing Interest Statement

GDM, DIV, SDV, TAI, ZOV, LDY, NBS and GAL report patents for a Sputnik V immunobiological expression vector, pharmaceutical agent, and its method of use to prevent COVID-19. LD, MG, MS, CF, BA, GG, FM, GAR, PV, VF, declare no conflict of interest. AA declares no conflict of interest for the present work, and, outside of the present work, declares honoraria for consultancy, lectures or research grants from Gilead, Merck, Astra Zeneca, Roche, ViiV, GSK, Janssen, Mylan, Theratecnologies. EG declares no conflict of interest for the present work, and, outside of the present work, declares honoraria for consultancy, lectures or research grants from Gilead, ViiV, Mylan.

Funding Statement

This study was funded by Russian Direct Investment Fund.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the INMI Ethical Committee (issue n. 297/2021) and Gamaleya NRCEM Local Ethics Committee (Protocol No. 17 of December 03, 2021).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 19, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals
D Lapa, DM Grousova, G Matusali, S Meschi, F Colavita, A Bettini, G Gramigna, M Francalancia, AR Garbuglia, E Girardi, V Puro, A Antinori, AV Kovyrshina, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, OV Zubkova, DY Logunov, BS Naroditsky, F Vaia, AL Gintsburg
medRxiv 2022.01.15.22269335; doi: https://doi.org/10.1101/2022.01.15.22269335
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals
D Lapa, DM Grousova, G Matusali, S Meschi, F Colavita, A Bettini, G Gramigna, M Francalancia, AR Garbuglia, E Girardi, V Puro, A Antinori, AV Kovyrshina, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, OV Zubkova, DY Logunov, BS Naroditsky, F Vaia, AL Gintsburg
medRxiv 2022.01.15.22269335; doi: https://doi.org/10.1101/2022.01.15.22269335

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (898)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8774)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1858)
  • Geriatric Medicine (178)
  • Health Economics (387)
  • Health Informatics (1288)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10549)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1750)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (963)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1842)
  • Public and Global Health (3977)
  • Radiology and Imaging (652)
  • Rehabilitation Medicine and Physical Therapy (343)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)